Ubiquitination and Deubiquitination: From Molecular Mechanisms to Therapeutic Strategies
Abstract
ABSTRACT Ubiquitination and deubiquitination are established as a reversible regulatory system controlling protein stability, localization, molecular interactions, and signaling duration. Ubiquitin is recognized not merely as a proteasomal degradation signal but as a molecular code whose output is determined by substrate identity, chain topology, and cellular context. Distinct ubiquitin signals are generated by E3 ubiquitin ligases (E3 ligases), remodeled by deubiquitinating enzymes (DUBs), and decoded by ubiquitinbinding domains. Beyond protein turnover, epigenetic and epitranscriptomic factors are directly regulated by ubiquitin signaling through control of their stability, activity, and interactions, thereby integrating chromatin and RNA regulation. In this review, the ubiquitin activating enzyme (E1)/ubiquitin conjugating enzyme (E2)/E3 cascade, ubiquitin chain architectures, DUBs, and signal recognition mechanisms are outlined in relation to key biological processes. The contribution of disrupted networks to cancer, neurodegeneration, and autoimmune diseases is discussed. Therapeutic strategies, including proteolysis targeting chimeras (PROTACs), molecular glues, DUB inhibitors, and E3 modulators, are presented with early clinical and preclinical developments highlighted to link mechanistic biology to therapeutic design. Shared principles of degradative and nondegradative ubiquitin signaling are identified across cellular networks, with emphasis on epigenetic and epitranscriptomic regulation. A nuanced framework is offered to interpret disease dysfunction, evaluate targeted therapies, and prioritize unresolved questions regarding substrate specificity and signaling context.